Evidence map›Paper›PMID 40482963›Full record

ArticleNew biotechnology2025

Sprinkling in extra validation for high-value PTMs and therapeutic Abs with MILKSHAKE Western blots and Sundae ELISAs.

Qiana Mendez, Srinivas S Thota, Jason J Oliveira, Hannah J Crary, Suchetana Saha, Kezzia S Jones, Lourdes Perez, Felicity Acca, Cassandra D Chapados, Holland A Driscoll and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in New biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Qiana MendezAbbratech, 25 Business Park Drive, Branford, Connecticut, USA.
Srinivas S ThotaTango Biosciences, 2201 W. Campbell Park Drive, Chicago, IL, USA.
Jason J OliveiraAbbratech, 25 Business Park Drive, Branford, Connecticut, USA.
Hannah J CraryAbbratech, 25 Business Park Drive, Branford, Connecticut, USA.
Suchetana SahaProteoWise, Inc., 85 Willow Street, New Haven, CT, USA.
Kezzia S JonesAbbratech, 25 Business Park Drive, Branford, Connecticut, USA.
Lourdes PerezAbbratech, 25 Business Park Drive, Branford, Connecticut, USA.
Felicity AccaAbbratech, 25 Business Park Drive, Branford, Connecticut, USA.
Cassandra D ChapadosAbbratech, 25 Business Park Drive, Branford, Connecticut, USA.
Holland A DriscollAbbratech, 25 Business Park Drive, Branford, Connecticut, USA.
Xiaofeng LiAbbratech, 25 Business Park Drive, Branford, Connecticut, USA.
Gregory R MirandoAbbratech, 25 Business Park Drive, Branford, Connecticut, USA.
Mikhail A KostylevProteoWise, Inc., 85 Willow Street, New Haven, CT, USA.
Erik C GuntherProteoWise, Inc., 85 Willow Street, New Haven, CT, USA.
Brian K KayTango Biosciences, 2201 W. Campbell Park Drive, Chicago, IL, USA.
Michael P WeinerAbbratech, 25 Business Park Drive, Branford, Connecticut, USA.
Mary R FergusonAbbratech, 25 Business Park Drive, Branford, Connecticut, USA. Electronic address: mferguson@abbratech.com.

Funding

A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12DR44GM149009 · NIGMS · PRECISION BIOTOOLS INC · PI Sara T Passos · 2025 to 2026
$2.4M
Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins.R44GM146473 · NIGMS · ABBRATECH, INC. · PI WEINER, MICHAEL P · 2023 to 2024
$2.2M
DIRECTED DISCOVERY AND VALIDATION OF ANTI-SPLICE-JUNCTION SITE AbsR44GM156476 · NIGMS · ABBRATECH, INC. · PI MICHAEL P WEINER · 2024 to 2026
$1.1M
Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins. I. survey of existing antibodies, and II. development of method improvementsR43GM146473 · NIGMS · ABBRATECH, INC. · PI WEINER, MICHAEL P · 2022 to 2022
$339k
NIGMS NIH HHS R43 GM146473NIGMS NIH HHS R44 GM146473NIGMS NIH HHS R44 GM149009NIGMS NIH HHS R44 GM156476
6 · The paper itself

Abstract

Thoroughly validated antibodies (Abs) are crucial for the generation of meaningful scientific data. Abs for post translationally modified (PTM) protein targets in particular pose added validation challenges. The MILKSHAKE method employs surrogate proteins which are either modified or non-modified at a specific site. Western blot is used to observe the binding of PTM Abs to the surrogate proteins, indicating the specificity of the PTM Ab under test. In this study, we expand the utility of MILKSHAKE by validating acetyl and methyl specific Abs and by introducing another surrogate protein antigen based on cellulose binding domain (CBD) to evaluate Abs in a single western blot lane. This study also explores the use of 'Sundae' surrogate protein ELISA specifically for therapeutic Ab evaluation.

Indexed as

AntibodiesBlotting, WesternProtein Processing, Post-TranslationalAnimalsEnzyme-Linked Immunosorbent AssayHumansAntibodiesAntibodyELISAPost translational modificationSortase ligationValidationWestern blot

Identifiers

PMID40482963
PMCPMC13227950

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.